If you have been reading about vaccine adjuvant and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The museum currently includes material on the early missionary dentists in Chengdu, historical dental equipment, teaching materials and records of the development of the West China dental school. The stomatological health education museum opened in September 2015 as a public science education center dedicated to oral medicine and health, and was designated a National Science Popularization Education Base.
=== Mass separation === The traditional IM-MS instrument uses a time‐of‐flight (TOF) mass spectrometer interfaced to an IMS. The TOF-MS has many advantages including the high speed of data acquisition and good sensitivity. Since mass spectral data is acquired on a microsecond time scale, multiple mass spectra are collected for each IMS spectrum (acquired on millisecond timescale). The quadrupole mass spectrometer has also been coupled to an IMS, although at a slower scan rate. Other mass spectrometers including the ion trap, Fourier transform ion cyclotron resonance (FT-ICR), or magnetic sector mass spectrometers have also been coupled with different IMS for various applications. Additionally, hybrid mass spectrometers have been interfaced to more than one ion mobility cell for tandem or IMSn–MSm applications.
This refrigeration method cools a contained area by melting ice, by sublimating dry ice, or evaporating liquid nitrogen. A simple example of this is a portable cooler, where ice is poured over the items that need to be refrigerated, keeping them cool and insulated from heat. Regular ice maintains freezing temperatures, but not below the freezing point, unless salt is used to cool the ice down further (as in a traditional ice-cream maker). Mixtures of other solvents with coolants like water ice, dry ice, or liquid nitrogen are also used to make cooling baths for chemistry. Dry ice can reliably bring the temperature well below the freezing point of water, to as low as 195K.
Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance. A 2026 systematic review on ADHD medication tolerance found evidence of tolerance developing to some affective state effects of amphetamine (e.g., positive mood and drug liking) within two weeks of daily use, but little to no evidence of long-term tolerance to its therapeutic or cardiovascular effects.
Sources: en.wikipedia.org
=== Sites of synthesis === Traditionally, RBP is synthesized within the liver with secretion being dependent upon retinol concentrations. However, the concentrations levels do not appear to have an effect upon transcription of RBP messenger RNA (mRNA) which remains constant. Literature reveals that the bovine endometrium has also been identified as a location of RBP synthesis, as well as, the conceptus and extraembryonic tissues of various livestock species.
Osedax is a genus of siboglinid polychaetes, commonly called snot worms, bone-eating worms, or zombie worms. Osedax is Latin for 'bone devourer', derived from the worms' unique ecological niche of bone-boring. Osedax settle on a bone, then secrete an acid through specialized root tissues to dissolve the bone's external layers in order to access the lipids within. Osedax act as ecosystem engineers, enhancing the biodiversity of bones they inhabit by increasing their structural complexity, allowing microfauna to inhabit otherwise inaccessible regions of the internal bone. Scientists from the Monterey Bay Aquarium Research Institute using the submarine ROV Tiburon first discovered the genus in Monterey Bay, California, in February 2002. The worms were found living on the bones of a decaying gray whale in the Monterey Canyon, at a depth of 2,893 m (9,491 ft).
Vitamin B12 deficiency can potentially cause severe and irreversible damage, especially to the brain and nervous system. At levels only slightly below normal, deficiency can result in fatigue, headaches, feeling faint, rapid breathing, pale skin, numbness or tingling, poor appetite, heartburn, poor balance, difficulty walking, poor reflexes, blurred vision, memory problems, depression, irritability, inattention, cognitive decline, dementia, and even psychosis. Among other problems, weakened immunity, reduced fertility and interruption of blood circulation in women may occur. It has also been linked to optic nerve atrophy and neuritis. The main type of vitamin B12 deficiency anemia is pernicious anemia, characterized by a triad of symptoms:
In a 12-week randomized controlled trial, modafinil significantly improved nighttime wakefulness as measured by sleep latency testing, reduced attention lapses, and lowered the rate of accidents or near-accidents during the commute home from work. However, residual sleepiness remained substantial even with treatment, and modafinil did not fully normalize alertness to daytime levels. A separate trial found that modafinil also improved patient functioning and mental health-related quality of life in shift workers. A Cochrane review concluded that modafinil and armodafinil increase alertness and reduce sleepiness in shift workers to some extent, but noted that evidence remains limited and the drugs are associated with adverse events including headache and nausea. Modafinil performs moderately as a drug to overcome excessive daytime sleepiness caused by obstructive sleep apnea. People with apnea should typically use a continuous positive airway pressure apparatus to prevent apnea before starting modafinil. When obstructive sleep apnea is comorbid with narcolepsy, modafinil is an effective drug to reduce the associated excessive daytime sleepiness. Both the American Academy of Sleep Medicine and European guidelines strongly recommend modafinil as a first-line treatment for narcolepsy. In France, modafinil is the first-line pharmacological treatment for excessive daytime sleepiness in narcolepsy, with methylphenidate designated as second-line.
=== 15 March === Hemedti vowed to carry out new offensives on March 17, the anniversary of the RSF's founding, claiming the RSF had undergone several changes and had made alliances with other groups such as the SPLM-N. He threatened to invade Port Sudan and attack Atbara, Shendi, Merowe, Al Dabbah, and Dongola. He also said that countries supporting the SAF would "pay the price". The bodies of 11 people suspected to have been killed by the RSF were recovered from a well in the Fayhaa neighborhood of Khartoum.
Sources: en.wikipedia.org
The Clinical Hemostasis Handbook. Chicago: Year Book Medical Publishers. Laposata, M. (2010–2013). Coagulation Disorders. Quality in Laboratory Diagnosis series. New York: Demos Medical Publishing. Laposata was also editor of the full six-volume series (Laboratory Management, Clinical Microbiology, Transfusion Medicine, Clinical Chemistry, Hematology/Clinical Immunology, and Coagulation Disorders). Laposata, M. (2016). Clinical Diagnostic Tests: How to Avoid Errors in Ordering Tests and Interpreting Results. New York: Demos Medical Publishing. Laposata, M.; McCaffrey, P. (2022). Clinical Laboratory Methods: Atlas of Commonly Performed Tests and Molecular Test Methods. New York: McGraw-Hill. Laposata, M., ed. (2025). Laposata's Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory (4th ed.). Lange Series. New York: McGraw-Hill. Laposata, M.; Dighe, A. S. (2007). "'Pre-pre' and 'post-post' analytical error: High-incidence patient safety hazards involving the clinical laboratory." Clinical Chemistry and Laboratory Medicine. 45: 712–719. Laposata, M. (2014). "Putting the patient first: Using the expertise of laboratory professionals to produce rapid and accurate diagnoses." Laboratory Medicine. 45: 4–5. Graber, M. L.; Rusz, D.; Jones, M. L.; Farm-Franks, D.; Jones, B.; Cyr Gluck, J.; Thomas, D. B.; Gleason, K.; Welte, K.; Abfalter, J.; Westerhaus, K.; Adams, G.; Laposata, M.; Eichbaum, Q.; Nabatchi, T.; Compton, M. (2017). "The new diagnostic team." Diagnosis. 4: 225–238.
=== Discontinued === Amibegron (SR-58611; SR-58611A) – β3-adrenergic receptor agonist [26] BTG-1640 (ABIO-08/01; ABIO-0801) – undefined mechanism of action [27] Darigabat (CVL-865; PF-06372865; PF-6372865) – GABAA receptor positive allosteric modulator [28] Imagabalin (PD-0332334; PD-332334; PF-00195889) – α2δ subunit-containing voltage-gated calcium channel ligand [29] Naluzotan (PRX-00023) – serotonin 5-HT1A receptor agonist and sigma σ1 receptor agonist [30] Ocinaplon (CL-273547) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [31] Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [32] PF-572778 – undefined mechanism of action [33] Rufinamide (Banzel; CGP-33101; E-2080; Inovelon; RUF-331; SYN-111) – sodium channel blocker and other actions [34] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [35] Tedatioxetine (Lu-AA24530) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), serotonin 5-HT2A, 5-HT2C, and 5-HT3 receptor antagonist, and α1A-adrenergic receptor antagonist [36]
CEEs are naturally occurring estrane steroids. They are in conjugate form, as the sodium salts of the C17β sulfate esters. The estrogens in CEEs, in their unconjugated active forms, include bioidentical human estrogens like estradiol and estrone as well as equine-specific estrogens such as equilin and 17β-dihydroequilin. The equine estrogens differ from human estrogens in that they have additional double bonds in the B ring of the steroid nucleus. CEEs contain both 17β-estrogens like estradiol and 17β-dihydroequilin and the C17α epimers like 17α-estradiol and 17α-dihydroequilin.
Food drying is a method of food preservation in which food is dried (dehydrated or desiccated). Drying inhibits the growth of bacteria, yeasts, and mold through the removal of water. Dehydration has been used widely for this purpose since ancient times; the earliest known practice is 12,000 B.C. by inhabitants of the modern Asian and Middle Eastern regions. Water is traditionally removed through evaporation by using methods such as air drying, sun drying, smoking or wind drying, although today electric food dehydrators or freeze-drying can be used to speed the drying process and ensure more consistent results.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.